FDA-Approves-Rybrevant-Faspro-for-Subcutaneous-Injection

Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffThe FDA approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech) for subcutaneous injection for adult patients across all indications approved for the IV formulation of amivantamab (Rybrevant, Janssen). See the prescribing information for the specific indications.The subcutaneous injection of amivantamab and hyaluronidase-lpuj was evaluated in PALOMA-3, a randomized, open-la